Low-dose IFN-α monotherapy in treatment-naive individuals with HIV-1 infection:: Evidence of potent suppression of viral replication
Low-dose IFN-α monotherapy in treatment-naive individuals with HIV-1 infection:: Evidence of potent suppression of viral replication
复制标题
DOI：
10.1089/107999001753238114
复制
发表时间：
2001-10-01
影响因子：
2.3
通讯作者：
Stalgis, C
中科院分区：
文献类型：
--
作者：
Hatzakis, A;Gargalianos, P;Stalgis, C
为了评估干扰素- α (ifn - α)在HIV-1感染中的安全性和抗病毒作用，我们在27名未接受治疗的患者中进行了概念验证研究。符合条件的患者包括两组：IFN-alpha组（n = 17），每天接受5 MIU IFN-alpha s.c.，连续32天；IFN-alpha NT组（n = 10），在高活性抗逆转录病毒治疗（HAART）之前未接受IFN-alpha治疗，两组均于第28天开始接受HAART治疗。完成研究的IFN-alpha组的17名患者中，有14名患者对IFN-alpha治疗耐受良好。在第14天，ifn -alpha组的HIV RNA平均减少量为1.1 log（10）。病毒载量抑制与基线病毒载量呈负相关（p = 0.031）。开始HAART治疗4周后，ifn - α和ifn - α NT组患者的HIV RNA较基线分别减少2.40和1.82 log,() （p < 0.001）。在ifn - α单药治疗初始血浆病毒载量下降1 log（10）后HIV-RNA反弹的患者中，没有证据表明与现有抗逆转录病毒药物产生交叉耐药。因此，每天低的ifn - α在体内表现出强大的抗hiv -1活性，而没有严重的副作用。这些特性使得ifn - α作为HAART的组成部分成为进一步评估的有吸引力的候选者。
To evaluate the safety and antiviral action of interferon-alpha (IFN-alpha) in HIV-1 infection, we undertook a proof of concept study in 27 treatment-naive patients. Eligible patients comprised two groups: the IFN-alphaT group (n = 17), which received 5 MIU IFN-alpha s.c. daily for 32 consecutive days, and the IFN-alpha NT group (n = 10), which did not receive IFN-alpha prior to highly active antiretroviral therapy (HAART), which was commenced on day 28 in both groups. IFN-alpha treatment was well tolerated in 14 of the 17 patients of the IFN-alphaT group who completed the study. The mean HIV RNA reduction in the IFN-alphaT group on day 14 was 1.1 log(10). Viral load suppression was inversely associated with baseline viral load (p = 0.031). Four weeks after initiation of HAART, IFN-alphaT and IFN-alpha NT group patients had 2.40 and 1.82 log,() HIV RNA reduction from baseline, respectively (p < 0.001). There was no evidence of cross-resistance with existing antiretrovirals in patients with HIV-RNA rebound after initial plasma viral load decline 1 log(10) during IFN-alpha monotherapy. Thus, low daily IFN-alpha exhibits potent anti-HIV-1 activity in vivo without serious adverse effects. These properties render IFN-alpha an attractive candidate for further assessment as a constituent of HAART.